Targeted therapies for rare lung diseases

Avalyn is a clinical-stage biopharmaceutical company developing targeted medicines for the treatment of rare respiratory diseases including idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases (ILD). ILDs are characterized by scarring, decline in lung function, reduced exercise capacity and quality of life, and increased mortality risk. Currently approved therapeutic options slow ILD progression but are associated with significant toxicities, which restrict their use and dosing. Avalyn is developing a pipeline of inhaled medicines designed to reduce systemic exposure and deliver the medication to the site of disease. AP01, Avalyn’s lead candidate, is a Phase 2b-ready inhaled formulation of pirfenidone optimized for delivery via inhalation. In a recent clinical study of two doses assessed in 91 individuals with IPF, AP01 demonstrated the potential to improve both efficacy and safety over existing therapy.

For more information on Avalyn please contact us at:

Full website coming February 2023